Lexeo Therapeutics CEO sells $19,090 in stock

Published 21/02/2025, 23:14
Lexeo Therapeutics CEO sells $19,090 in stock

Richard Nolan Townsend, the Chief Executive Officer of Lexeo Therapeutics , Inc. (NASDAQ:LXEO), recently sold a portion of his shares in the company. The transaction comes as the stock trades near its 52-week low of $3.84, having declined over 73% in the past year. According to InvestingPro analysis, the company appears undervalued at its current market capitalization of $149 million. According to a filing with the Securities and Exchange Commission, Townsend sold 4,326 shares of common stock on February 19, 2025, at an average price of $4.413 per share. The total value of the transaction amounted to $19,090.

This sale was conducted to cover tax obligations related to the release of restricted stock units. Following the transaction, Townsend retains ownership of 220,119 shares, including 136,562 restricted stock units.

In other recent news, Lexeo Therapeutics has announced the appointment of Dr. Kyle Rasbach as its new Chief Financial Officer. Dr. Rasbach brings a wealth of experience in life sciences and financial management, having previously held positions at Zentalis Pharmaceuticals, Eventide Asset Management, and T. Rowe Price. His appointment comes at a pivotal time as Lexeo Therapeutics prepares for significant advancements in its gene therapy programs. The company is actively developing treatments for cardiovascular diseases and APOE4-associated Alzheimer’s disease. Lexeo’s CEO, R. Nolan Townsend, expressed optimism about Dr. Rasbach’s addition to the team, citing his track record in strategic planning and business development. The company is focusing on a stepwise development approach, supported by early proof-of-concept data. Additionally, Lexeo’s forward-looking statements about its product candidates and clinical trials are subject to risks and uncertainties as outlined in their SEC filings. These developments indicate a strategic move by Lexeo to bolster its financial and operational capabilities as it advances its therapeutic pipeline.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.